Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 02, 2025 10:30 ET | Source: 4D Path

4D Path Presents Breakthrough Research Demonstrating That Its Unique Digital Predictive Biomarker Identifies Treatment Responders in a Difficult-To-Treat Breast Cancer Patient Population

4D Path QPORTM platform delivers unprecedented predictive insights for patients with low immune infiltrates—achieving a 66% response rate
June 02, 2025 09:00 ET | Source: IGI, Inc.

Full Dose-Escalation Data Show Continued High Response Rates and Favorable Safety Profile of ISB 2001, a First-in-Class BCMA × CD38 × CD3 Trispecific Antibody, for the Treatment of Relapsed/Refractory Multiple Myeloma

Ichnos Glenmark Innovation presented full results of TRIgnite-1 study of ISB 2001 at ASCO showing continued high response rate and favorable safety profile
June 02, 2025 08:02 ET | Source: Pasithea

Pasithea Therapeutics Presents Updated Interim Data from Ongoing Phase 1 Study of PAS-004 at the ASCO Annual Meeting 2025

PAS-004 shows early signs of efficacy and strong tolerability in Phase 1 cancer trial, with tumor reductions and disease stability in pre-treated patients
May 31, 2025 08:00 ET | Source: https://immatics.com/

Immatics IMA203 PRAME Cell Therapy Data Presented at 2025 ASCO Annual Meeting Continues to Show Strong Anti-tumor Activity and Durability in Patients with Metastatic Melanoma

Extended Phase 1b trial follow-up on IMA203 PRAME cell therapy in 33 heavily pretreated patients with metastatic melanoma demonstrates favorable tolerability and promising clinical activity with...
May 05, 2025 07:00 ET | Source: IGI, Inc.

Ichnos Glenmark Innovation (IGI) Receives U.S. FDA Fast Track Designation for ISB 2001 for Relapsed/Refractory Multiple Myeloma

IGI, Inc., today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for ISB 2001.
April 24, 2025 07:02 ET | Source: Pasithea

Pasithea Therapeutics to Present Updated Data from Ongoing Phase 1 Trial of PAS-004 in Advanced Cancer Patients at the 2025 ASCO Annual Meeting

Pasithea Tx (Nasdaq: KTTA) will present updated Phase 1 data for MEK inhibitor PAS-004 in MAPK-driven cancers at ASCO 2025 on June 2 in Chicago.
April 23, 2025 11:45 ET | Source: Transgene S.A.

Transgene communiquera, dans une présentation orale rapide, de nouvelles données de Phase I du vaccin thérapeutique individualisé TG4050 à l’ASCO 2025

Strasbourg, France – Le 23 avril 2025, 17 h 45 – Transgene (Euronext Paris : TNG), société de biotechnologie qui conçoit et développe des immunothérapies contre le cancer reposant sur des vecteurs...
April 23, 2025 11:45 ET | Source: Transgene S.A.

Transgene to Provide Updated Phase I Data in a Rapid Oral Presentation on Individualized Therapeutic Cancer Vaccine TG4050 at ASCO 2025

Strasbourg, France, April 23, 2025, 5:45 p.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, will be...
April 23, 2025 10:00 ET | Source: https://immatics.com/

Immatics Announces Upcoming Oral and Poster Presentation on IMA203 TCR T-cell Therapy at 2025 ASCO Annual Meeting

Houston, Texas and Tuebingen, Germany, April 23, 2025 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company active in the discovery and development of...